FDA Committee Weighs EUA for Another COVID-19 Vaccine Tomorrow
February 25, 2021
The Food and Drug Administration (FDA) Vaccines and Related Biologics Advisory Committee will meet tomorrow beginning at 9 a.m. to consider an Emergency Use Authorization (EUA) for the COVID-19 vaccine developed by Johnson & Johnson’s Janssen Pharmaceutical division. The meeting will be available to view virtually at this link, where you can also review documents on the vaccine trials. View the agenda for the meeting here.
Previously, this advisory committee of experts also reviewed the Pfizer and Moderna vaccines and recommended an EUA shortly after their deliberations concluded. Review of the Johnson & Johnson vaccine, which requires just one dose unlike the Pfizer and Moderna vaccines, comes as new variants of the virus are spreading. The committee will weigh how these variants will impact the new vaccine’s effectiveness. Johnson & Johnson reported that in a study of nearly 44,000 volunteers the single shot showed a 66 percent effectiveness in protecting participants from moderate or severe coronavirus disease.
For a comprehensive look at the issues the committee will be considering, this article from Healthcare Dive gives a good overview.
If approved, the Johnson & Johnson vaccine could, in time, help alleviate some of the supply issues and help meet the demand of those waiting to be vaccinated.